205 results about "Malaria" patented technology

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of malarial protein antigens and related technologies (e.g., components thereof and / or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding malarial protein antigens.

The invention discloses a malaria-related biomarker detection chip based on an integrated organic electrochemical transistor as well as a preparation method and application of the malaria-related biomarker detection chip. According to the malaria-related biomarker detection chip based on the integrated organic electrochemical transistor, the integrated organic electrochemical transistor comprises an insulating substrate, a source electrode, a drain electrode and a gate electrode, the source electrode, the drain electrode and the gate electrode are arranged on the top of the insulating substrate, and an organic conductive channel is arranged between the source electrode and the drain electrode; the gate electrode and the organic conductive channel are located on the same plane, the gate electrode is a three-dimensional gold electrode obtained on the surface of a two-dimensional gold electrode by adopting an electrochemical deposition method, and the surface of the three-dimensional gold electrode is modified with a single-stranded DNA aptamer for identifying malaria-related biomarkers. The invention can realize high-sensitivity detection of malaria-related biomarkers, and has important significance for early diagnosis of diseases.

The invention belongs to the technical field of biomedicine, and particularly relates to application of Ackermania muciniphila in improvement and treatment of cerebral malaria caused by Plasmodium berghei. The invention tries to evaluate the effect of the AKK bacterium on improving and treating the cerebral malaria of a mouse under the condition that the AKK bacterium or auxiliary medicines (dihydroartemisinin, rapamycin and atorvastatin) are independently used on a cerebral malaria model of the mouse. Results indicate that the strain can effectively improve behavioristics of mice and immune pathological injuries of all organs, reduce protozoemia and prolong the lifetime of the mice whether the strain is independently used or combined with the drugs, and compared with the strain which is independently used with the drugs, the strain can effectively treat cerebral malaria of the mice. As ackermania muciniphila is common probiotics in human intestinal tracts, the three drugs (dihydroartemisinin, rapamycin and atorvastatin) used in the invention are all clinically used drugs, and if the drugs are clinically transformed to treat human brain malaria caused by plasmodium falciparum, the feasibility is high, and meanwhile, the transformation time can be shortened. According to the invention, a bacterium-medicine synergistic concept is provided for the first time, that is, probiotics can assist medicines in treating diseases, and a solution is provided for treating human cerebral malaria under the guidance of the concept.

Methods of treating malaria comprising administration of compounds of Formula (I′) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

Provided are methods for treatment of pathological conditions causing hemolysis, cerebral edema, acute kidney injury and non-anaphylactic shock, including envenomation, trauma, cerebral malaria and mast-cell diseases using at least one PLA2 inhibitor, alone or in combination with other agents. The unexpected versatility of PLA2 inhibitors, their dosage forms and combinations make them candidates as essential medicines for the developing world.

Provided are methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Also provided are uses of the compounds of Formula (I), as defined herein, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

The invention relates to the technical field of microbial pharmacy, and discloses an Aspergillus thermofuscus KLWNF12 strain, a fermentation product of the Aspergillus thermofuscus KLWNF12 strain and an anti-infection application of the Aspergillus thermofuscus KLWNF12 strain, and the preservation number of the Aspergillus thermofuscus KLWNF12 strain is CGMCC No.40716. The Aspergillus pyruvus KLWNF12 provided by the invention has unique secondary metabolite production capacity, and has important application value in the fields of pathogenic bacterium resistance, malaria resistance and the like. In addition, the invention further provides a method for preparing an anti-pathogenic-bacterium and anti-malaria product by using the aspergillus thermofuscus KLWNF12, and a new thought and a new technical means are provided for developing novel anti-infection drugs.

The present invention is related to new compounds useful in the manufacture of a medicament for preventing or treating malaria, pharmaceutical compositions, methods of preparation and uses thereof.

The utility model discloses a portable multifunctional malaria diagnosis and treatment tool box which comprises a box body and a box cover, a storage space is formed in the box body, and the box cover is rotationally connected with the box body; the partition plate is arranged in the box body, at least two positioning rods are arranged in vertical through grooves in the left side wall and the right side wall of the storage space, the positioning rods and the side wall of the partition plate are oppositely arranged, and positioning holes are formed in the positioning rods; the at least two barrier plates are arranged between the side wall of the partition plate and the positioning rod; the blocking column is arranged on the blocking plate; the transverse through hole is formed in the side wall of the storage space and is communicated with the vertical through groove; when the positioning rod moves to the first position, the blocking columns make contact with a rod body of the positioning rod, the partition plates are clamped between the blocking plates, the positions of the partition plates are fixed, the partition plates cannot move along with shaking of the tool box, and the probability that articles in the storage space fall off and shake is effectively reduced; when the positioning rod moves to the second position, the blocking column is arranged in the positioning hole, and a gap is formed between the blocking plate and the partition plate, so that the partition plate can be conveniently moved to change the size of the storage space, the device is portable and multipurpose, and the diagnosis and treatment requirements of malaria in outdated and remote areas are met.

The present invention relates to pharmaceutical preparations containing as active ingredients 3-N-formylhydroxylaminopropylphosphonic acid derivatives or 3-N-acetylhydroxylaminopropylphosphonic acid derivatives in combination with clindamycin and artesunate for the treatment of malaria, in particular for the acute therapy of cerebral malaria, and to an associated dosage, in particular for the patient group of children.

The present disclosure provides anti-circumsporozoite (CSP) antibodies, compositions containing such antibodies, methods for producing the disclosed antibodies, and methods for using them to treat or prevent malaria, as well as methods for selecting antibodies as anti-malaria therapeutic antibodies.

This invention provides compounds for the treatment, prevention, or suppression of various pathological conditions (such as proliferative disorders like cancer, β-globin disorders, fibrosis, pain, neurodegenerative diseases, Prader-Willi syndrome, malaria, viral infections, myopathy, and autism) by inhibiting G9a. [Solution] The following general formula (I) TIFF2026062914000401.tif2449 A compound represented by or a pharmacoposly acceptable salt thereof is provided.

The present disclosure provides compositions (e.g., pharmaceutical compositions) and related techniques (e.g., components thereof and / or methods related thereto) for delivery of malaria protein antigens. The present disclosure provides, among other things, polyribonucleotides encoding malaria protein antigens.

According to the purposes of the present disclosure, as embodied and broadly described herein, the present disclosure relates, in one aspect, to scaffold molecules that exhibit potent anti-malarial activity against a variety of Plasmodium strains at different stages of a parasite, such as the red and infrared stages, and pharmaceutical compositions comprising the scaffold molecules. In one aspect, these compounds are tetrahydroacridones having Structure I described herein. In another aspect, the compounds described herein may be used to treat or prevent malaria in a subject.

Highly specific T cells and T-cell receptors (TCRs) specific to a pathogen associated with an infectious disease can be generated by ex vivo induction or expansion, which can be useful for developing therapeutics such as vaccines for infectious diseases and determining antigen presentation in vitro. The present disclosure provides malaria-specific TCRs and nucleic acid encoding the TCRs, methods of making T cells specific for an infectious disease, methods of identifying TCRs, and methods of using the same for determining whether a vaccine induces T cell specific immune response, whether an epitope sequence is presented, and whether an antigen is recognizable by TCRs.

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of malarial protein antigens and related technologies (e.g., components thereof and / or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding malarial protein antigens.

The invention discloses an antibody pair, a reagent and a method for detecting malaria, and relates to the field of immunodiagnosis. The antibody pair for detecting malaria disclosed by the invention comprises the first antibody and the second antibody, and the reagent and the detection method based on the antibody pair can accurately detect the existence of malaria.

Compounds of formula (I) or their pharmaceutically acceptable salts, hydrates, solvates, esters or their optical isomers, racemates, diastereoisomers, enantiomers, tautomers, or a mixture thereof; said compounds exhibits anti-plasmidal activities, in particular for the treatment of malaria diseases.

The invention discloses an antibody pair, a reagent and a method for detecting malaria, and relates to the field of immunodiagnosis. The antibody pair for detecting malaria disclosed by the invention comprises the first antibody and the second antibody, and the reagent and the detection method based on the antibody combination can accurately detect the existence of malaria.

The present disclosure provides anti-circumsporozoite (CSP) antibodies, compositions comprising such antibodies. Also disclosed are methods of producing the disclosed antibodies and methods of treating or preventing malaria using the same.

A method for the treatment of malaria which comprises applying microwave energy to a patient under non-thermal conditions. The non-thermal conditions are achieved by applying the microwave energy under conditions that the normal heating effects of microwaves are not significant. For example, microwave energy may be switched on in pulses lasting less than 6 seconds.

Subject matter of the present invention is an angiotensin-receptor-agonist and / or a precursor thereof for use in the treatment of a disease in a subject, • wherein said disease is selected from the group comprising heart failure, chronic heart failure, acute heart failure (AHF), myocardial infarction (MI), stroke, liver failure, burn injuries, traumatic injuries, severe infection (microbial, viral (e.g. AIDS), parasitic diseases (e.g. Malaria)), SIRS or sepsis, cancer, acute kidney injury (AKI), CNS disorders (e.g. seizures, neurodegenerative diseases), autoimmune diseases, vascular diseases, hypotension and shock, and • wherein said subject has an amount of DPP3 protein and / or DPP3 activity in a sample of bodily fluid that is above a predetermined threshold.

A combination of a carrier sheet (6) and a mosquito net (1), wherein the mosquito net (1) comprises a mesh fabric (5) formed as a canopy to cover a bedding area and protect humans from insects, the carrier sheet (6) is made of a flexible material and has edges attached to the mesh fabric (5) optionally by sewing, and the carrier sheet (6) is loaded with a functional item for medical diagnosis, such as a malaria test kit.

The present application generally relates to compounds, pharmaceutical compositions and method to treat a patient with malaria related disease or Plasmodium infection. Particularly the method compromises the step of administering a therapeutically effective amount of the disclosed compounds or compositions, with or without one or more anti-infective agents, to the patient in need of relief from said infection. Methods of uses and composition matters are within the scope of this disclosure.

The present invention discloses an artemisinin PROTACs, a preparation method and application thereof, wherein the structural formula is: The present invention uses artemisinin modified product artesunate as POI ligand, lenalidomide and pomalidomide as E3 ligands, and linkers selected from amino acid chains, PEG chains and fatty chains. The anticancer activity thereof is superior to that of artesunate, and the present invention has good potential application prospects in anticancer drugs and treatment of critical malaria.

An herbal composition comprising Harungana madagascariensis, Carissa edulis, Justicia betonica, Alstonia boonei, Zanthoxylum gillettii, Prunus africana, Newtonia buchananii, and combinations thereof for treating malaria.

Provided herein are eupenifeldin derivatives, compositions comprising these eupenifeldin derivatives, and methods of using thereof for the treatment of cancer, parasitic infections (e.g., malaria), fungal infections, and bacterial infections.

The utility model relates to the technical field of medical detection, in particular to a malaria colloidal gold kit capable of improving rapid detection efficiency, which comprises a kit body and a blood taking needle, the side wall of the kit body is provided with two notches, and the inner side of the kit body is fixedly provided with detection test paper; a clamping structure is mounted on the kit body and comprises a rotating shaft I rotationally connected to the side wall of the kit body. The blood taking needle is clamped and fixed through the clamping structure, so that the kit body is provided with the disposable blood taking needle in a matched mode, the disposable blood taking needle does not need to be cleaned after being used, the detection speed is greatly increased, dropped blood and buffering agents can be stirred through the stirring structure, and the detection accuracy is improved. Therefore, the mixing of the blood and the buffering agent is promoted.

The invention discloses an antibody pair, a reagent and a method for detecting malaria, and relates to the field of immunodiagnosis. The antibody pair for detecting malaria disclosed by the invention comprises the first antibody and the second antibody, and the reagent and the detection method based on the antibody pair can accurately detect the existence of malaria.

The present invention belongs to the field of biomedical technology, and specifically relates to an application of DHA@ZIF-8 in treating mouse cerebral malaria. The present invention first establishes a mouse cerebral malaria model, then uses ZIF-8@DHA on the model for treatment, and observes the therapeutic effect of the nano drug on mouse cerebral malaria by behavioral, pathological, molecular biological and other technical means; the present invention uses ZIF-8 as a carrier to achieve the effect of sustained release of the drug, thereby extending its action time in the body to more effectively kill malarial parasites. Compared with natural administration, the action time of DHA is extended.